Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

The latest price target for Passage Bio (NASDAQ:PASG) was reported by Chardan Capital on March 4, 2025. The analyst firm set a price target for $6.00 expecting PASG to rise to within 12 months (a ...

For PASG, shares are up 24.26% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 3.78% over the same time period.

Passage Bio (PASG) announced new interim results from the first six patients in its Phase 1/2 study for PBGM01 targeted at GM1 Gangliosidosis ((GM1)), Read full story here.

Passage Bio (PASG) shares surged 9% on encouraging Phase 1/2 data for gene therapy candidate PBFT02 in treating FTD-GRN, a type of early onset dementia. Read more here.

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...